London-based nutrition company Zoe has raised $15 million in a Series B investment round. This funding will be used to expand the company's presence in the United States. Zoe is known as a platform that offers its users at-home test kits to analyze blood fat, blood sugar and gut microbiome health. Based on the test results, it gives each food a score between 0 and 100, helping users make healthy eating choices.

Zoe

Zoe guides customers on how to change, add and combine foods. For example, instead of toast with peanut butter, banana and sliced almonds, a user might be suggested to eat toast with cream cheese, avocado and chia seeds. Users can monitor their overall health while improving their gut microbiome with these recommendations. Jonathan Wolf, CEO of Zoe, stated that thanks to these personalized approaches, users have observed positive changes in both physical and mental health. Zoe participated in a randomized controlled trial published in Nature Medicine that examined the effects of personalized nutrition programs on cardiometabolic health.

The new investment contributed to Zoe raising a total of $118 million in funding. This funding will help the company increase its presence in the US and reach a wider customer base. Wolf said they will invest more in marketing in the US, emphasizing that there are millions of people who can benefit from Zoe's services. Wolf noted that Zoe is not just focused on weight loss, but instead aims to improve overall health. With the new funding, Zoe will focus on marketing efforts to expand its customer base in the US and introduce its products to a wider audience.